NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis $36.00 -0.32 (-0.88%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$35.98 -0.02 (-0.06%) As of 08/7/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Apogee Therapeutics Stock (NASDAQ:APGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Apogee Therapeutics alerts:Sign Up Key Stats Today's Range$35.26▼$36.7950-Day Range$36.00▼$47.5552-Week Range$26.20▼$63.50Volume489,316 shsAverage Volume716,840 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$99.00Consensus RatingBuy Company Overview Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts. Read More Apogee Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreAPGE MarketRank™: Apogee Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 493rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingApogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApogee Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Apogee Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Apogee Therapeutics are expected to decrease in the coming year, from ($3.09) to ($3.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apogee Therapeutics is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apogee Therapeutics is -10.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApogee Therapeutics has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Apogee Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.62% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Apogee Therapeutics has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.62% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Apogee Therapeutics has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. News and Social Media4.0 / 5News Sentiment1.19 News SentimentApogee Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Apogee Therapeutics this week, compared to 4 articles on an average week.Search Interest8 people have searched for APGE on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows7 people have added Apogee Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $555,674.00 in company stock.Percentage Held by Insiders42.77% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apogee Therapeutics' insider trading history. Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APGE Stock News HeadlinesApogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic ...August 5 at 9:25 PM | theglobeandmail.comJefferies Sticks to Its Buy Rating for Apogee Therapeutics (APGE)July 27, 2025 | theglobeandmail.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)Apogee Therapeutics Reports Positive Phase 2 Trial ResultsJuly 27, 2025 | theglobeandmail.comBTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy RatingJuly 16, 2025 | finance.yahoo.comCanaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)July 14, 2025 | msn.comStifel reiterates Buy rating on Apogee Therapeutics stock amid positive ...July 11, 2025 | investing.comApogee Therapeutics Shares Surge After Promising Eczema Drug Trial ResultsJuly 9, 2025 | msn.comSee More Headlines APGE Stock Analysis - Frequently Asked Questions How have APGE shares performed this year? Apogee Therapeutics' stock was trading at $45.30 at the beginning of 2025. Since then, APGE shares have decreased by 20.5% and is now trading at $36.00. How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics Inc. (NASDAQ:APGE) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.24. When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering (IPO) on Friday, July 14th 2023. The company issued 17,650,000 shares at $15.00-$17.00 per share. Who are Apogee Therapeutics' major shareholders? Apogee Therapeutics' top institutional investors include Jennison Associates LLC (0.59%), Bank of New York Mellon Corp (0.44%), TD Asset Management Inc (0.21%) and Platinum Investment Management Ltd. (0.19%). Insiders that own company stock include Nimish P Shah, Michael Thomas Henderson, Carl Dambkowski, Jane Henderson and Mark C Mckenna. View institutional ownership trends. How do I buy shares of Apogee Therapeutics? Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Apogee Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apogee Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/12/2025Today8/08/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APGE CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Price Target for Apogee Therapeutics$99.00 High Price Target$116.00 Low Price Target$89.00 Potential Upside/Downside+175.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$182.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-28.35% Return on Assets-26.98% Debt Debt-to-Equity RatioN/A Current Ratio15.82 Quick Ratio15.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.92 per share Price / Book2.26Miscellaneous Outstanding Shares46,050,000Free Float26,353,000Market Cap$1.66 billion OptionableOptionable Beta1.43 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:APGE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.